Treatment
TNF Inhibitor clinical trials
We’re tracking 12 recruiting studies that include TNF Inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT05428488RecruitingPhase 3
Step-by-step treatment for rheumatoid arthritis with TNF medicine
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
Montpellier, FranceAges 18 years+ - NCT06538870Recruiting
Dental implant healing and TNF-alpha blockers
This study looks at how dental implants heal in people who take TNF-alpha inhibitors (medicines that lower inflammation) compared to those who don't. It aims to see if the drug affects healing after implant surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07545317Recruiting
IL-23 Inhibitors for Active Crohn's Disease
This study follows patients with moderate-to-severe Crohn's disease who are starting a newer type of biologic medication called IL-23 inhibitors (guselkumab or risankizumab). Researchers want to understand how well these drugs work in real-world clinical practice and compare their effectiveness to other treatments.
Guangzhou, GuangdongAges 18–75 - NCT06712628Recruiting
Comparing how long people stay on upadacitinib vs TNF inhibitors for RA
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT04731831Recruiting
Testing how well TNF medicines work in inflammatory arthritis
This study looks at how your immune system responds to starting infliximab or adalimumab for rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Results may help doctors understand why some people don’t respond as well and how to improve treatment.
AalborgAges 18 years+ - NCT05590455RecruitingPhase 2
Testing a TNF-blocking drug to reduce death in HIV and TB meningitis
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
Rio de JaneiroAges 18 years+ - NCT06653634RecruitingPhase 4
Optimizing treatment for kids with JIA in remission
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
BergenAges 2–17 - NCT07166315Recruiting
Comparing new treatments for arthritis of the spine or joints
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
Bath, SomersetAges 18 years+ - NCT07554820RecruitingPhase 4
Heart Protection in Rheumatoid Arthritis With New Medications
This study compares two treatment approaches for people with active rheumatoid arthritis who also have heart disease risk factors. It tests whether a newer drug called tofacitinib, combined with cholesterol medication, can better protect the heart than traditional TNF-inhibitor treatments.
Lahore, Punjab ProvinceAges 50–85 - NCT05950724Enrolling by invitationEarly Phase 1
TNF blocker to protect lungs after transplant
This early-stage trial tests whether blocking a specific inflammation signal (TNF-alpha) can help prevent or improve kidney problems and early graft (new lung) dysfunction after a lung transplant at Northwestern. You might be eligible if you’re scheduled for that transplant and are willing to go through study consent and follow-up.
Chicago, IllinoisAges 18 years+ - NCT07137598RecruitingPhase 2
A study of RO7790121 for moderate to severe rheumatoid arthritis
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
Peoria, ArizonaAges 18 years+ - NCT06642207Recruiting
Comparing two biologic drugs for ankylosing spondylitis
This study compares two types of biologic drugs (IL-17 inhibitors vs. anti-TNF drugs) in people with ankylosing spondylitis (a form of arthritis affecting the spine) who have already tried standard treatments. The goal is to see which drug works better for controlling symptoms.
SohagAges 16–60
What TNF Inhibitor is being studied for
Conditions with recruiting TNF Inhibitor studies.
Common questions
- Are there clinical trials studying TNF Inhibitor?
- Yes. Clin2 currently lists 12 recruiting studies that include TNF Inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a TNF Inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is TNF Inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether TNF Inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.